
The Blue Box Biomedical Solutions offers a urine-based, pain-free screening test that detects breast cancer earlier and more reliably than mammography for many women. The device pairs an electronic nose sensor array with AI algorithms to identify urinary biomarkers, achieving 88.42% sensitivity and improved detection in women with dense breasts. It operates as a Diagnostics-as-a-Service B2B solution aimed at gynecology clinics and plans clinical trials before commercial rollout. Pilot studies involved over 450 women across seven hospitals and the company targets improved screening for women aged 20–49.

The Blue Box Biomedical Solutions offers a urine-based, pain-free screening test that detects breast cancer earlier and more reliably than mammography for many women. The device pairs an electronic nose sensor array with AI algorithms to identify urinary biomarkers, achieving 88.42% sensitivity and improved detection in women with dense breasts. It operates as a Diagnostics-as-a-Service B2B solution aimed at gynecology clinics and plans clinical trials before commercial rollout. Pilot studies involved over 450 women across seven hospitals and the company targets improved screening for women aged 20–49.
Product: Urine-based, point-of-care breast cancer screening device (proprietary eNose + AI)
Reported performance: Sensitivity reported around 83%–88% (company pilot data)
Clinical evidence: Pilot studies across ~7 hospitals with ~450+ patients per pilot
Business model: Diagnostics-as-a-Service, B2B targeting gynecology clinics
Founding location: Barcelona, Spain (EU HQ)
Early breast cancer screening and non-invasive diagnostics
2021
Biotechnology
Multiple investors reported; Crunchbase lists a Seed round announced in 2025.
“Multiple seed-stage investors including venture funds, accelerators, family offices and nonprofit cancer association participation”